Final Analysis of a Trial of M72/AS01 <sub>E</sub> Vaccine to Prevent Tuberculosis

Tait, Dereck; Hatherill, Mark; Van Der Meeren, Olivier; M. Ginsberg, Ann; van Brakel, Elana; Salaun, Bruno; J. Scriba, Thomas; Jacqueline Akité, Elaine; Ayles, Helen; Bollaerts, Anne; Demoitié, Marie‐Ange; H. Diacon, Andreas; G. Evans, Thomas; Gillard, Paul; Hellström, Elizabeth; C. Innes, James; Lempicki, Maria; Malahleha, Mookho; Martinson, Neil; Mesia Vela, Doris; Muyoyeta, Monde; Nduba, Videlis; Pascal, Thierry; Tameris, Michèle; Thienemann, Friedrich; J. Wilkinson, Robert; Roman, François

doi:10.1056/nejmoa1909953

Public

Final Analysis of a Trial of M72/AS01 E Vaccine to Prevent Tuberculosis

Published in New England Journal of Medicine • Oct 29, 2019

Authors:

Dereck Tait

Mark Hatherill

Olivier Van Der Meeren

Abstract

Background Results of an earlier analysis of a trial of the M72/AS01E candidate vaccine against Mycobacterium tuberculosis showed that in infected adults, the vaccine provided 54.0% protection against active pulmonary tuberculosis disease, without evident safety concerns. We now report the results o...

Subject

Immunogenicity

Medicine

Tuberculosis

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!